Methods for treatment of cancer

Abstract

A method for treating or preventing cancer in a subject comprising administering a treatment effective amount of a chemotype 4 compound.

1 - 29 . (canceled) 
     
     
         30 . A compound of Formula (III) or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein,
 R3 is carbocycloalkyl; 
 R4 is selected from alkyl, branched alkyl, cycloalkyl, and H; and 
 R5 is halogen, lower alkyl, haloalkyl, alkylether, —NH 2 , mono-substituted amine, di-sub stituted amine, cyclic amine, or H. 
 
       
     
     
         31 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is selected from halogen, lower alkyl, haloalkyl, alkylether, and H. 
     
     
         32 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is F, Cl, Br or I. 
     
     
         33 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is methyl, ethyl or propyl. 
     
     
         34 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is —CF 3 . 
     
     
         35 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is —OCH 3 . 
     
     
         36 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is H. 
     
     
         37 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is morpholine, pyrrolidine, piperazine or piperidine. 
     
     
         38 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is H, F, Cl, OCH 3 , CH 3 , CN, NO 2 , or NH 2 . 
     
     
         39 . The compound or pharmaceutically acceptable salt according to  claim 30 , wherein R5 is selected from H, F, and Cl. 
     
     
         40 . A compound of Formula (IV) or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein,
 R3 is carbocycloalkyl; 
 R4 is selected from alkyl, branched alkyl, cycloalkyl, and H; 
 R5 is halogen, lower alkyl, haloalkyl, alkylether, —NH 2 , mono-substituted amine, di-sub stituted amine, cyclic amine, or H; 
 R6 is H or alkyl; 
 R7 is H or alkyl; and 
 R8 is H or alkyl. 
 
       
     
     
         41 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is selected from halogen, lower alkyl, haloalkyl, alkylether, and H. 
     
     
         42 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is F, Cl, Br or I. 
     
     
         43 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is methyl, ethyl or propyl. 
     
     
         44 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is —CF 3 . 
     
     
         45 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is —OCH 3 . 
     
     
         46 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is H. 
     
     
         47 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is morpholine, pyrrolidine, piperazine or piperidine. 
     
     
         48 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is H, F, Cl, OCH 3 , CH 3 , CN, NO 2 , or NH 2 . 
     
     
         49 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein R5 is selected from H, F, and Cl. 
     
     
         50 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein
 R5 is H, F, or Cl;   R6 is H or CH 3 ;   R7 is H or CH 3 ; and   R8 is H or CH 3 .   
     
     
         51 . The compound or pharmaceutically acceptable salt according to  claim 40 , wherein
 R5 is H;   R6 is H;   R7 is H; and   R8 is H.